Latest Conference

Milena McLaughlin, PharmD, MSc, explains ways to remain vigilant when it comes to drug shortages.

Elizabeth Phillips, MD, FRCPC, FRACP, addresses the misconceptions about penicillin allergies.

Meghan Jeffres, PharmD, discusses the utility of penicillin skin testing for patients labeled as penicillin allergic.

Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.

Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.

Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.

Snigdha Vallabhaneni, MD, MPH, shares actions patients and their visitors can take to protect themselves from Candida auris.

Pedro Cahn, MD, explains the new formulation of raltegravir HD.

Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.

Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.

A phase 2a clinical trial has found the dapivirine vaginal ring to be a safe and acceptable means for HIV prevention in adolescents, who showed notably high adherence when using the ring.

The NIH has released the findings of the first of 2 early-stage clinical trials on assessing the safety and effectiveness of HIV candidate vaccinations that support additional development of vaccines.

Phase 2 study finds that the use of daily oral Truvada as a means of HIV prevention is safe and acceptable.

Peter Williams, PhD, discusses the LATTE-2 trial for HIV treatment.

Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.

Researchers reported at the 9th IAS Conference on HIV Science that a HIV-infected child who had been treated in infancy has maintained remission without drugs since 2008.

Ariane van der Straten, PhD, MPH, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.

A recent study finds that the majority of HIV-infected transgender women are anxious about taking ART and feminizing hormone therapy simultaneously due to hazardous drug interactions.

Leah Johnson, PhD, discusses the biomedical HIV prevention implant that is being developed by RTI International.

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.

WHO and IAS come together to create the first-ever global research prioritization agendas at the 9th IAS Conference on HIV Science in Paris, France.

The results of a phase 2 trial for a 2-drug regimen of long-acting cabotegravir and rilpivirine and a 3-drug regimen in patient with HIV showed comparable viral suppression rates at 96 weeks.

Arjun Srinivasan, MD, stresses the importance of surgical teams speaking up if they have safety concerns regarding procedure in operating rooms.

Jason Pogue, PharmD, BCPS-ID, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.

Milena McLaughlin, PharmD, MSc, explains the best way to determine an alternative agent during a drug shortage.

Caetano Sabino, BSc, discusses how antimicrobial photodynamic therapy could be used to complement antimicrobial chemotherapy in order to manage drug-resistant infections.

Jason Gallagher, PharmD, BCPS, FCCP, FIDSA, explains how restrictions on commercial automated susceptibility testing can affect patient care.

Snigdha Vallabhaneni, MD, MPH, recommends ways for caretakers to protect themselves from acquiring Candida auris.